查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2007875

個人化癌症疫苗市場預測至2034年—按疫苗類型、給藥途徑、技術、應用、最終用戶和地區分類的全球分析

Personalized Cancer Vaccines Market Forecasts to 2034 - Global Analysis By Vaccine Type, Delivery Method, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球個人化癌症疫苗市場規模將達到 14 億美元，並在預測期內以 27.4% 的複合年成長率成長，到 2034 年將達到 98 億美元。

個人化癌症疫苗是指透過活化患者自體免疫系統，對抗源自於患者自體惡性細胞基因組定序的腫瘤特異性抗原而研發的個人化免疫療法製劑。這些製劑包括基於新抗原的胜肽製劑、mRNA遞送製劑、樹突狀細胞製劑和DNA疫苗載體。它們透過生物資訊驅動的新抗原預測和快速生產流程製造，用於治療黑色素瘤、肺癌和其他固體癌患者，以誘導針對患者特異性癌症突變的細胞毒性T細胞反應。

mRNA技術的成熟

mRNA技術的成熟是推動個人化新抗原癌症疫苗規模化、快速生產的變革性動力，而先前這一過程需要數月時間。新冠疫苗計畫已證實，脂質奈米顆粒遞送系統的最佳化可直接應用於癌症疫苗製劑，從而縮短生產週期並提高有效載荷穩定性。大型製藥企業正在加速投資其個人化mRNA癌症疫苗研發管線，建構後期臨床資產組合，並驗證其商業化路徑的可行性。

製造複雜性和成本

生產過程的複雜性和每位患者高昂的生產成本限制了個人化癌症疫苗的普及。每種疫苗都需要在臨床可接受的時限內進行個別基因組定序、新抗原優先排序以及客製化胜肽或mRNA合成。對先進的GMP生物製造基礎設施和高技能人員的需求顯著增加了固定成本。這些障礙對缺乏癌症治療預算柔軟性的醫療系統而言尤其不利，使得目前的商業性可行性僅限於高階市場。

聯合免疫療法通訊協定

將個人化癌症疫苗與查核點抑制劑結合的聯合免疫療法通訊協定展現出巨大的發展潛力，因為越來越多的臨床證據表明，其協同腫瘤緩解率高於任何單一療法。腫瘤科醫師和保險公司也越來越接受組合方案，只要其持續療效能夠抵銷成本。監管機構正在簡化腫瘤聯合治療的快速核准流程，為個人化疫苗研發商與成熟的查核點抑制劑生產商合作，以加速產品商業化進程鋪路。

查核點抑制劑的競爭格局

已通過核准的查核點抑制劑的競爭格局已然形成，這對個人化癌症疫苗的市場推廣構成了重大威脅。這是因為腫瘤科醫師依賴那些療效成熟、醫保報銷機製完善且被納入臨床指引的藥物。要在大型臨床試驗中證明其療效優於現有標準療法，需要大量投資，並面臨巨大的監管風險。患者和醫生對實驗性個人化療法作為成熟治療方法替代方案的抵觸情緒，進一步限制了其在臨床試驗框架之外的短期應用。

新冠疫情的影響：

新冠疫情大大加速了個人化癌症疫苗的研發，因為它展示了mRNA遞送平台和脂質奈米顆粒的大規模生產。疫情期間，疫苗技術開發人員和腫瘤學專家之間的合作創造了技術轉移的機會，並縮短了研發週期。疫情後，監管機構推出了適用於個人化癌症療法的簡化版、適應性強的臨床試驗指南，為研發管線帶來了結構性優勢。

在預測期內，DNA疫苗細分市場預計將成為最大的細分市場。

由於DNA疫苗相比mRNA疫苗具有更優異的穩定性、成熟的生產過程以及在黑色素瘤和肺癌等適應症領域不斷拓展的後期臨床試驗管線，預計在預測期內，DNA疫苗將佔據最大的市場佔有率。 DNA疫苗無需低溫儲存，提高了在不同臨床環境中的物流可行性。多項評估個人化DNA疫苗平台合併查核點抑制劑的III期臨床試驗正在產生積極的中期數據，為商業性前景提供了有力支撐。

預計基因測序領域在預測期內將呈現最高的複合年成長率。

在預測期內，基因組定序領域預計將呈現最高的成長率，這主要得益於全EXOME顯子定序成本的快速下降以及主要醫療系統臨床基因組學基礎設施的擴展。隨著美國和歐洲保險覆蓋範圍的擴大，基因組定序在腫瘤分析中的實用化正在加速發展。將次世代定序工作流程直接整合到醫院腫瘤科的診療流程中，使得新抗原數據成為個人化疫苗生產流程中不可或缺的關鍵資訊。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的臨床試驗基礎設施、在個性化腫瘤學領域主導的生物製藥投資，以及包括FDA突破性療法和加速核准在內的有利法規環境。美國擁有大多數處於後期階段的個人化癌症疫苗臨床計畫。高昂的抗癌藥物支出和基因組分析的健保覆蓋，為已通過核准的個人化疫苗產品早期進入市場創造了有利的商業性條件。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於癌症患者數量的快速成長、各國政府對基因組醫療基礎設施的投資，以及中國、日本和韓國臨床試驗活動的不斷擴大。亞太地區主要經濟體的國家癌症控制計畫正在將基因組腫瘤分析納入標準診斷流程。日本和中國對創新腫瘤生技藥品的快速監管核准流程，正加速個人化疫苗開發商進入市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需要進行可行性測試）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 成長動力、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章：全球個人化癌症疫苗市場：依疫苗類型分類

  • 基於新抗原的疫苗
  • 樹突細胞疫苗
  • 基於mRNA的疫苗
  • 基於胜肽的疫苗
  • DNA疫苗
  • 癌細胞疫苗
  • 其他疫苗類型

第6章：全球個人化癌症疫苗市場：依給藥途徑分類

  • 靜脈注射
  • 皮下
  • 皮內注射
  • 肌肉內部
  • 奈米顆粒遞送
  • 脂質奈米顆粒

第7章：全球個人化癌症疫苗市場：依技術分類

  • 基因組定序
  • 次世代定序（NGS）
  • 生物資訊平台
  • 免疫資訊學
  • 人工智慧驅動的疫苗設計
  • 單細胞分析

第8章：全球個人化癌症疫苗市場：按應用領域分類

  • 黑色素瘤
  • 肺癌
  • 乳癌
  • 攝護腺癌
  • 結腸癌
  • 骨髓惡性腫瘤
  • 其他用途

第9章：全球個人化癌症疫苗市場：依最終用戶分類

  • 醫院
  • 腫瘤診所
  • 研究機構
  • 生技公司
  • 製藥公司
  • 臨床試驗中心
  • 其他最終用戶

第10章：全球個人化癌症疫苗市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Moderna Inc.
  • BioNTech SE
  • Gritstone bio, Inc.
  • CureVac NV
  • Roche Holding AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Novartis AG
  • Sanofi SA
  • Genentech Inc.
  • Immatics NV
  • ISA Pharmaceuticals
  • Neon Therapeutics
  • Nouscom AG
  • Transgene SA
  • Adaptimmune Therapeutics
Product Code: SMRC34761

According to Stratistics MRC, the Global Personalized Cancer Vaccines Market is accounted for $1.4 billion in 2026 and is expected to reach $9.8 billion by 2034 growing at a CAGR of 27.4% during the forecast period. Personalized cancer vaccines refer to individualized immunotherapeutic constructs designed to prime the patient's immune system against tumor-specific antigens derived from genomic sequencing of their own malignant cells. They encompass neoantigen-based peptide formulations, mRNA delivery constructs, dendritic cell preparations, and DNA vaccine vectors. Manufactured through bioinformatics-driven neoantigen prediction and rapid manufacturing workflows, they are administered to melanoma, lung cancer, and other solid tumor patients, stimulating cytotoxic T-cell responses against patient-specific cancer mutations.

Market Dynamics:

Driver:

mRNA Technology Maturation

mRNA technology maturation is a transformative driver enabling scalable, rapid manufacturing of personalized neoantigen cancer vaccines that previously required months of production. Lipid nanoparticle delivery optimization validated through COVID-19 vaccine programs has directly transferred to oncology vaccine formulation, reducing manufacturing cycle times and improving payload stability. Major pharmaceutical entities are accelerating personalized mRNA cancer vaccine pipeline investments, generating late-stage clinical asset portfolios and substantiating commercial pathway feasibility.

Restraint:

Manufacturing Complexity and Cost

Manufacturing complexity and prohibitive per-patient production costs constrain personalized cancer vaccine accessibility, as each vaccine requires individual genomic sequencing, neoantigen prioritization, and bespoke peptide or mRNA synthesis within clinically meaningful timeframes. Sophisticated GMP biomanufacturing infrastructure and highly skilled personnel requirements elevate fixed costs substantially. These barriers disproportionately restrict access in healthcare systems with limited oncology drug budget flexibility, confining current commercial viability to premium market segments.

Opportunity:

Combination Immunotherapy Protocols

Combination immunotherapy protocols integrating personalized cancer vaccines with checkpoint inhibitors present a major opportunity, as clinical evidence increasingly demonstrates synergistic tumor response rates exceeding either modality alone. Oncology physicians and payers are showing growing acceptance of combination regimens where response durability justifies combined costs. Regulatory agencies are streamlining accelerated approval frameworks for combination oncology approaches, creating faster commercial pathways for personalized vaccine developers partnering with established checkpoint inhibitor manufacturers.

Threat:

Competitive Checkpoint Inhibitor Landscape

The entrenched competitive landscape of approved checkpoint inhibitors represents a significant threat to personalized cancer vaccine commercial adoption, as oncologists rely on well-characterized agents with established reimbursement and clinical guideline inclusion. Demonstrating superior efficacy versus existing standard of care in pivotal trials requires substantial investment and carries meaningful regulatory risk. Patient and physician resistance to experimental personalized approaches in lieu of proven therapies further constrains near-term uptake beyond clinical trial settings.

Covid-19 Impact:

COVID-19 profoundly accelerated personalized cancer vaccine development by validating mRNA delivery platforms and lipid nanoparticle manufacturing at scale. Pandemic-era partnerships between vaccine technology developers and oncology specialists created technology transfer opportunities that compressed development timelines. Post-pandemic, regulatory agencies introduced streamlined adaptive trial guidance applicable to personalized oncology therapeutics, structurally benefiting the pipeline.

The DNA-based vaccines segment is expected to be the largest during the forecast period

The DNA-based Vaccines segment is expected to account for the largest market share during the forecast period, due to their stability advantages over mRNA constructs, established manufacturing processes, and growing late-stage clinical pipeline across melanoma and lung cancer indications. DNA vaccines do not require ultra-cold storage, improving logistical feasibility for diverse clinical settings. Multiple Phase III trials evaluating personalized DNA vaccine platforms in combination with checkpoint inhibitors are generating positive interim data supporting commercial expectations.

The genomic sequencing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Genomic Sequencing segment is predicted to witness the highest growth rate, driven by rapidly declining whole-exome sequencing costs and expanding clinical genomics infrastructure in major healthcare systems. Real-world genomic sequencing adoption for tumor profiling is accelerating as reimbursement coverage expands in the U.S. and Europe. The integration of next-generation sequencing workflows directly into hospital oncology pathways is generating the neoantigen data inputs essential for personalized vaccine manufacturing pipelines.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to advanced clinical trial infrastructure, leading biopharmaceutical investment in personalized oncology, and supportive regulatory environments including FDA breakthrough therapy and accelerated approval designations. The United States hosts the majority of late-stage personalized cancer vaccine clinical programs. High oncology drug expenditure and insurance coverage for genomic profiling create commercial conditions supporting early market penetration for approved personalized vaccine products.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding oncology patient populations, government investments in genomic medicine infrastructure, and growing clinical trial activity across China, Japan, and South Korea. National cancer control programs in major Asia Pacific economies are integrating genomic tumor profiling into standard diagnostic workflows. Accelerated regulatory approval pathways for innovative oncology biologics in Japan and China are facilitating faster market entry for personalized vaccine developers.

Key players in the market

Some of the key players in Personalized Cancer Vaccines Market include Moderna Inc., BioNTech SE, Gritstone bio, Inc., CureVac N.V., Roche Holding AG, Merck & Co., Inc., Pfizer Inc., AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Genentech Inc., Immatics N.V., ISA Pharmaceuticals, Neon Therapeutics, Nouscom AG, Transgene SA, and Adaptimmune Therapeutics.

Key Developments:

In March 2026, Moderna Inc. announced expansion of its personalized cancer vaccine manufacturing capacity through a new U.S.-based GMP production facility partnership.

In February 2026, Roche Holding AG entered a co-development agreement to evaluate personalized neoantigen vaccine combination regimens with atezolizumab across multiple solid tumor types.

In January 2026, BioNTech SE reported positive Phase II data for its individualized neoantigen mRNA cancer vaccine combined with pembrolizumab in advanced melanoma patients.

In October 2025, Gritstone bio, Inc. initiated a Phase II clinical trial evaluating its GRANITE neoantigen cancer vaccine in combination with checkpoint immunotherapy for colorectal cancer.

Vaccine Types Covered:

  • Neoantigen-based Vaccines
  • Dendritic Cell Vaccines
  • mRNA-based Vaccines
  • Peptide-based Vaccines
  • DNA-based Vaccines
  • Tumor Cell Vaccines
  • Other Vaccine Types

Delivery Methods Covered:

  • Intravenous
  • Subcutaneous
  • Intradermal
  • Intramuscular
  • Nanoparticle Delivery
  • Lipid Nanoparticles

Technologies Covered:

  • Genomic Sequencing
  • Next-Generation Sequencing (NGS)
  • Bioinformatics Platforms
  • Immunoinformatics
  • AI-driven Vaccine Design
  • Single-cell Analysis

Applications Covered:

  • Melanoma
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Hematological Malignancies
  • Other Applications

End Users Covered:

  • Hospitals
  • Oncology Clinics
  • Research Institutes
  • Biotech Companies
  • Pharma Companies
  • Clinical Trial Centers
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Personalized Cancer Vaccines Market, By Vaccine Type

  • 5.1 Neoantigen-based Vaccines
  • 5.2 Dendritic Cell Vaccines
  • 5.3 mRNA-based Vaccines
  • 5.4 Peptide-based Vaccines
  • 5.5 DNA-based Vaccines
  • 5.6 Tumor Cell Vaccines
  • 5.7 Other Vaccine Types

6 Global Personalized Cancer Vaccines Market, By Delivery Method

  • 6.1 Intravenous
  • 6.2 Subcutaneous
  • 6.3 Intradermal
  • 6.4 Intramuscular
  • 6.5 Nanoparticle Delivery
  • 6.6 Lipid Nanoparticles

7 Global Personalized Cancer Vaccines Market, By Technology

  • 7.1 Genomic Sequencing
  • 7.2 Next-Generation Sequencing (NGS)
  • 7.3 Bioinformatics Platforms
  • 7.4 Immunoinformatics
  • 7.5 AI-driven Vaccine Design
  • 7.6 Single-cell Analysis

8 Global Personalized Cancer Vaccines Market, By Application

  • 8.1 Melanoma
  • 8.2 Lung Cancer
  • 8.3 Breast Cancer
  • 8.4 Prostate Cancer
  • 8.5 Colorectal Cancer
  • 8.6 Hematological Malignancies
  • 8.7 Other Applications

9 Global Personalized Cancer Vaccines Market, By End User

  • 9.1 Hospitals
  • 9.2 Oncology Clinics
  • 9.3 Research Institutes
  • 9.4 Biotech Companies
  • 9.5 Pharma Companies
  • 9.6 Clinical Trial Centers
  • 9.7 Other End Users

10 Global Personalized Cancer Vaccines Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Moderna Inc.
  • 13.2 BioNTech SE
  • 13.3 Gritstone bio, Inc.
  • 13.4 CureVac N.V.
  • 13.5 Roche Holding AG
  • 13.6 Merck & Co., Inc.
  • 13.7 Pfizer Inc.
  • 13.8 AstraZeneca plc
  • 13.9 GlaxoSmithKline plc
  • 13.10 Novartis AG
  • 13.11 Sanofi S.A.
  • 13.12 Genentech Inc.
  • 13.13 Immatics N.V.
  • 13.14 ISA Pharmaceuticals
  • 13.15 Neon Therapeutics
  • 13.16 Nouscom AG
  • 13.17 Transgene SA
  • 13.18 Adaptimmune Therapeutics

List of Tables

  • Table 1 Global Personalized Cancer Vaccines Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Personalized Cancer Vaccines Market Outlook, By Vaccine Type (2023-2034)($MN)
  • Table 3 Global Personalized Cancer Vaccines Market Outlook, By Neoantigen-based Vaccines (2023-2034)($MN)
  • Table 4 Global Personalized Cancer Vaccines Market Outlook, By Dendritic Cell Vaccines (2023-2034)($MN)
  • Table 5 Global Personalized Cancer Vaccines Market Outlook, By mRNA-based Vaccines (2023-2034)($MN)
  • Table 6 Global Personalized Cancer Vaccines Market Outlook, By Peptide-based Vaccines (2023-2034)($MN)
  • Table 7 Global Personalized Cancer Vaccines Market Outlook, By DNA-based Vaccines (2023-2034)($MN)
  • Table 8 Global Personalized Cancer Vaccines Market Outlook, By Tumor Cell Vaccines (2023-2034)($MN)
  • Table 9 Global Personalized Cancer Vaccines Market Outlook, By Other Vaccine Types (2023-2034)($MN)
  • Table 10 Global Personalized Cancer Vaccines Market Outlook, By Delivery Method (2023-2034)($MN)
  • Table 11 Global Personalized Cancer Vaccines Market Outlook, By Intravenous (2023-2034)($MN)
  • Table 12 Global Personalized Cancer Vaccines Market Outlook, By Subcutaneous (2023-2034)($MN)
  • Table 13 Global Personalized Cancer Vaccines Market Outlook, By Intradermal (2023-2034)($MN)
  • Table 14 Global Personalized Cancer Vaccines Market Outlook, By Intramuscular (2023-2034)($MN)
  • Table 15 Global Personalized Cancer Vaccines Market Outlook, By Nanoparticle Delivery (2023-2034)($MN)
  • Table 16 Global Personalized Cancer Vaccines Market Outlook, By Lipid Nanoparticles (2023-2034)($MN)
  • Table 17 Global Personalized Cancer Vaccines Market Outlook, By Technology (2023-2034)($MN)
  • Table 18 Global Personalized Cancer Vaccines Market Outlook, By Genomic Sequencing (2023-2034)($MN)
  • Table 19 Global Personalized Cancer Vaccines Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034)($MN)
  • Table 20 Global Personalized Cancer Vaccines Market Outlook, By Bioinformatics Platforms (2023-2034)($MN)
  • Table 21 Global Personalized Cancer Vaccines Market Outlook, By Immunoinformatics (2023-2034)($MN)
  • Table 22 Global Personalized Cancer Vaccines Market Outlook, By AI-driven Vaccine Design (2023-2034)($MN)
  • Table 23 Global Personalized Cancer Vaccines Market Outlook, By Single-cell Analysis (2023-2034)($MN)
  • Table 24 Global Personalized Cancer Vaccines Market Outlook, By Application (2023-2034)($MN)
  • Table 25 Global Personalized Cancer Vaccines Market Outlook, By Melanoma (2023-2034)($MN)
  • Table 26 Global Personalized Cancer Vaccines Market Outlook, By Lung Cancer (2023-2034)($MN)
  • Table 27 Global Personalized Cancer Vaccines Market Outlook, By Breast Cancer (2023-2034)($MN)
  • Table 28 Global Personalized Cancer Vaccines Market Outlook, By Prostate Cancer (2023-2034)($MN)
  • Table 29 Global Personalized Cancer Vaccines Market Outlook, By Colorectal Cancer (2023-2034)($MN)
  • Table 30 Global Personalized Cancer Vaccines Market Outlook, By Hematological Malignancies (2023-2034)($MN)
  • Table 31 Global Personalized Cancer Vaccines Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 32 Global Personalized Cancer Vaccines Market Outlook, By End User (2023-2034)($MN)
  • Table 33 Global Personalized Cancer Vaccines Market Outlook, By Hospitals (2023-2034)($MN)
  • Table 34 Global Personalized Cancer Vaccines Market Outlook, By Oncology Clinics (2023-2034)($MN)
  • Table 35 Global Personalized Cancer Vaccines Market Outlook, By Research Institutes (2023-2034)($MN)
  • Table 36 Global Personalized Cancer Vaccines Market Outlook, By Biotech Companies (2023-2034)($MN)
  • Table 37 Global Personalized Cancer Vaccines Market Outlook, By Pharma Companies (2023-2034)($MN)
  • Table 38 Global Personalized Cancer Vaccines Market Outlook, By Clinical Trial Centers (2023-2034)($MN)
  • Table 39 Global Personalized Cancer Vaccines Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.